Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006 Sep;8(9):626-33.
doi: 10.1111/j.1524-6175.2006.05411.x.

Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension

Affiliations
Randomized Controlled Trial

Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension

William B White et al. J Clin Hypertens (Greenwich). 2006 Sep.

Abstract

To attain recent goals of blood pressure (BP) control, multiple drug therapy combinations are required, including higher doses of thiazide diuretics in combination with other classes of antihypertensive drug therapy. Thus, the authors evaluated the antihypertensive effects of telmisartan vs valsartan when combined with hydrochlorothiazide (HCTZ) 25 mg in a large (N=1066), placebo-controlled trial in patients with stage 1 or 2 hypertension. The primary end points were the changes from baseline in seated diastolic and systolic BP at the end of the 8-week treatment period. Safety end points included adverse events, changes in laboratory parameters, and pulse rate. Changes from baseline in BP following telmisartan-HCTZ (-24.0/-17.6 mm Hg) were significantly greater than both placebo (-4.4/-6.8 mm Hg) and valsartan-HCTZ (-21.2/-16.1 mm Hg) (vs placebo, P<.001 for systolic and diastolic BP; vs valsartan-HCTZ, P=.004 for systolic BP and P=.019 for diastolic BP). The total number of patients with at least 1 adverse event reported were similar among the 3 treatment groups (placebo, 49%; telmisartan-HCTZ, 43%; and valsartan-HCTZ, 38%). In conclusion, telmisartan-HCTZ at doses of 80/25 mg lowered both systolic and diastolic BP to a greater extent than valsartan-HCTZ at doses of 160/25 mg. These data support using a higher dose of a thiazide diuretic (25 mg) with a long-acting angiotensin receptor blocker as a useful strategy for improving hypertension control.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Impact of age group (younger than 65 years vs 65 years and older) on changes from baseline in systolic and diastolic blood pressure (BP) for each of the treatment groups. HCTZ indicates hydrochlorothiazide.
Figure 2
Figure 2
Impact of gender on changes from baseline in systolic and diastolic blood pressure (BP) for each of the treatment groups. HCTZ indicates hydrochlorothiazide.
Figure 3
Figure 3
Impact of race (nonblack vs black) on changes from baseline in systolic and diastolic blood pressure (BP) for each of the treatment groups. HCTZ indicates hydrochlorothiazide.

Similar articles

Cited by

References

    1. Lewington S, Clarke R, Qizilbash N, et al, for the Prospective Studies Collaboration . Age‐specific relevance of usual blood pressure to vascular mortality: a meta‐analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–;1913. - PubMed
    1. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood‐pressure lowering and low‐dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755–;1762. - PubMed
    1. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–;2572. - PubMed
    1. European Society of Hypertension‐European Society of Cardiology. 2003. European Society of Hypertension‐European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011–;1054. - PubMed
    1. Ruddy MC, Kostis JB. Angiotensin receptor antagonists. In: Oparil S, Weber MA, eds. Hypertension. Philadelphia, PA: WB Saunders Co; 2000:621–;637.

Publication types

MeSH terms